Numares seeks FDA nod for NMR platform

By staff writers

March 24, 2021 -- Numares has submitted a 501(k) application to the U.S. Food and Drug Administration (FDA) for its Axinon nuclear magnetic resonance (NMR) IVD platform for metabolomics-based and artificial intelligence (AI)-driven diagnostics.

numares Axinon NMR system
The Axinon NMR system. Image courtesy of Numares.

Axinon aims to identify early kidney rejection in post-transplant surveillance, assess kidney function by improved determination of glomerular filtration rate, and ascertain risk for cardiovascular disease. If cleared, Axinon would become the first NMR-based clinical laboratory system to use AI-evaluated metabolic data, according to Numares.

Copyright © 2021

To read this and get access to all of the exclusive content on, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?